| 1 | Presidential report |
| 2 | Secretary General and Vice-Presidents reports |
| 3 | Treasurer Report |
| 4 | Re-Appointment of the Auditor |
| 5 | Presentation and approval of 2024-2026 elections for the members of the Executive Committee |
| 6 | Proposal for Constitution changes |
| 7 | EAACI President 2024-2026 address |
| 8 | Q&A Session |
Presidential report
EAACI Position Papers Published
STRENGTHENED HEADQUARTER

- Onboarding of new HQ manager
- Creation of new Education & Specialty team
- Strengthened the Marketing & Communication Team
- Restructuring to include remote team members
MEMBERSHIP GROWTH

Individual Members: 8,471
Junior Members: 7,393
IMPACT FACTOR OF EAACI JOURNALS

Allergy

- 2023 Impact Factor: 15.7
- (6,472 citations / 413 counted articles)

Pediatric Allergy and Immunology

- 2023 Impact Factor: 5.0
- (1,363 citations / 275 counted articles)

Clinical and Translational Allergy

- 2023 Impact Factor: 4.5
- (656 citations / 145 counted articles)
• The pivotal platform for the promotion of science and innovation within our community.

• The go-to place for the latest developments in allergy, asthma, and immunology -> fostering exchange with experts and helping us advance on our EAACI mission.
EAACI IS BACK WITH LIVE EVENTS
FOCUS MEETINGS & EDUCATIONAL EVENTS

2022

ALLERGY SCHOOL 2022
Cork, Ireland
Putting nutrition at the forefront of prevention and treatment of allergies and asthma

ISMA-RHINA Digital 2022
International Symposium on Molecular Allergology and the European Rhinology Meeting

FAAM - EUROBAT Digital 2022
1-3 December
Post Allergy and Anaphylaxis Meeting: European Conference on Implementation of Flow Cytometry in Allergy

2023

IMMUNOLOGY WINTER SCHOOL 2023
Basic Immunology Research in Allergy and Clinical Immunology
Basel, Switzerland
26-29 January

SAM DIGITAL 2023
24-25 March
EAACI-ESCD Skin Allergy Meeting

Master Class 2023
5-6 May, 2023
Madrid, Spain

ISAF Hybrid 2023
Zakopane, Poland
08-11 January

2024

Immunology Winter School 2024
Zakopane, Poland
08-11 January
Basic Immunology Research in Allergy and Clinical Immunology

Allergy School 2023
Izmir, Turkey
21-23 September
EAACI Allergy School on Anaphylaxis: Anaphylaxis Invited

DHM Hybrid 2023
Porto, Portugal
2-4 November
International Symposium on Proteomics

PAAM Hybrid 2023
Porto, Portugal
2-4 November
International Symposium on Proteomics
The groundbreaking hybrid format of the EAACI Congress 2022 in Prague where I took over as the new EAACI President.

The resounding success of the EAACI Congress in Hamburg last year has marked a significant milestone in our pivot to hybrid events.
Approval of the Presidential report
Secretary General report
Online Member services **re-imagined**
- **Our Vision:** a central platform for member activities offering Project and Task Force management, Budget approvals, Team calendars, Document management, and Voting.
- **Why:** streamline and improve experiences for our members
- **Current Status:** review of existing platforms and requirements analysis

**EAACI.org modernization**
- Strengthen the EAACI brand
  - Improve user experience
  - Focus on patients’ lives

**EAACI Handbook**
- Online resource providing the Executive Committee and the EAACI Family with essential information on the EAACI organisation, roles & responsibilities, and policies & processes.
Membership

Individual Members: 8,471
Junior Members: 7,369
Membership

Top Countries

1287 - Italy
1105 - Spain
1036 - United Kingdom
780 - Germany
688 - Turkey
524 - Russian Federation
498 - The Netherlands
484 - United States
452 - France
417 - Romania
Membership

Top International countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States</td>
<td>483</td>
</tr>
<tr>
<td>Brazil</td>
<td>382</td>
</tr>
<tr>
<td>India</td>
<td>363</td>
</tr>
<tr>
<td>Mexico</td>
<td>341</td>
</tr>
<tr>
<td>China</td>
<td>270</td>
</tr>
<tr>
<td>Canada</td>
<td>253</td>
</tr>
<tr>
<td>Australia</td>
<td>230</td>
</tr>
<tr>
<td>Japan</td>
<td>180</td>
</tr>
<tr>
<td>Republic of Korea</td>
<td>169</td>
</tr>
</tbody>
</table>
Membership

Junior Membership

<table>
<thead>
<tr>
<th>Year</th>
<th>Membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>3530</td>
</tr>
<tr>
<td>2014</td>
<td>3912</td>
</tr>
<tr>
<td>2015</td>
<td>4288</td>
</tr>
<tr>
<td>2016</td>
<td>4516</td>
</tr>
<tr>
<td>2017</td>
<td>4909</td>
</tr>
<tr>
<td>2018</td>
<td>5136</td>
</tr>
<tr>
<td>2019</td>
<td>5556</td>
</tr>
<tr>
<td>2020</td>
<td>6373</td>
</tr>
<tr>
<td>2021</td>
<td>6626</td>
</tr>
<tr>
<td>2022</td>
<td>7141</td>
</tr>
<tr>
<td>2023</td>
<td>7497</td>
</tr>
<tr>
<td>2024</td>
<td>7393</td>
</tr>
</tbody>
</table>
MyEAACI project

Implementation steps

<table>
<thead>
<tr>
<th>Year</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>Kick-off survey</td>
</tr>
<tr>
<td>2021</td>
<td>Annual survey</td>
</tr>
<tr>
<td>2022</td>
<td>Revised Dual Membership with NAS (Including reduced fee for annual congress)</td>
</tr>
<tr>
<td>2023</td>
<td>Annual survey</td>
</tr>
</tbody>
</table>

- **EAACI fellows programme**
- **Rewarding committed members** per EAACI membership length categories
- **Revitalizing NASC**
MyEAACI project

**1382 MEMBERS**

**43 AGREEMENTS**

37% MALE

63% FEMALE

**Age Groups**

- 36-45
- 51-60
- >60
- 46-50
- 31-35
- 25-30
- <25

**Top NAS Societies**

- Turkey (TNSACI)
- Spain (SEACI)
- United Kingdom (BSACI)
- Germany (DGAKI)
- Poland (PTA)
- Romania (RSACI)
- Portugal (SPAIC)
- France (SFA)
- Czech Republic (CSAKI)
- Italy (AAITO)

**Top Countries**

- Spain
- Turkey
- Germany
- United Kingdom
- Italy
- France
- Poland
- Portugal
- Romania
- Greece
MyEAACI project

2000 - Silver Member
600 - Gold Member
200 - Platinum Member
ACTION PLAN – COMMUNICATION PHASES

1. LISTEN

Communication Audit

Listening to current members to know their satisfaction level, needs and expectations. We will define the type of experience we want for them and identify the gaps.

2. DESIGN

Corp. Comms formalisation

Structuring a Corporate Communication Model that will play a strategic role within the organisation.

Defining narrative that will address the strengths, purpose and value that the EAACI adds and reshape the Member Value Proposition.

3. LAUNCH

Engagement campaign

Creation and implementation of an internal engagement campaign based on narrative, impact and segmentation, to boost members loyalty.

EXTERNAL: to put in place a plan to increase visibility in key media and social networks.
MyEAACI project

Tailored communication and branding

**EXCOM INTERVIEWS**
- In-depth interviews with:
  1. Cezmi Akdis
  2. Ibon Eguiluz
  3. Leticia de las Vecillas
  4. María José Torres

**Focus Groups**
- Clinicians and sanitarians
- Employees
- Junior Members
- National Allergy Societies
- Patient Organisations
- Researchers

**Documentary Analysis**
- Previous communications
- Previous surveys and reports

**Comparative Benchmark**

**ONLINE SURVEY**
1. Questionnaire elaboration
2. Pannel definition
3. Survey programming
4. Communication to panellists
5. Survey sending

**EXTERNAL INTERVIEWS**
1. Interviews with journalists & partners

**ANALISYS AND REPORT**
1. Qualitative information analysis
2. Quantitative information analysis

**INTERNAL REPORT & EXTERNAL REPORT**
New Working Groups

WG Mast Cell Diseases (Dermatology Section)
The proposed EAACI Working Group aims to be connected to ECNM, involve participants who are experts in this field (publications and expertise in MCD, an connect with other Sections-IG in the field of Hymenoptera, Drug Allergy and Immunology)

WG Angioedema (Dermatology Section)
The proposed EAACI Working Group aims at providing the EAACI and more generally the medical community with a dedicated panel of experts in the field of HAE.
Vice Presidents’ reports
VP Congresses
Mohamed Shamji
Vice-President Congresses
3 June 2024
EAACI Congress 2024
Valencia, Spain
31 May - 3 June

Revolutionising Patient Care Through the Power of Data Science

#EAACIcongress
www.eaaci.org
EAACI Hybrid 2024 – Registration Figures*

*as at 02 June 2024

<table>
<thead>
<tr>
<th>City</th>
<th>Year</th>
<th>Registration Figures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valencia</td>
<td>2024</td>
<td>8’047</td>
</tr>
<tr>
<td>Hamburg</td>
<td>2023</td>
<td>7’352</td>
</tr>
<tr>
<td>Prague</td>
<td>2022</td>
<td>7’082</td>
</tr>
<tr>
<td>Krakow</td>
<td>2021</td>
<td>7’122</td>
</tr>
<tr>
<td>Digital</td>
<td>2020</td>
<td>8’324</td>
</tr>
<tr>
<td>Lisbon</td>
<td>2019</td>
<td>8’733</td>
</tr>
<tr>
<td>Munich</td>
<td>2018</td>
<td>7’533</td>
</tr>
<tr>
<td>Helsinki</td>
<td>2017</td>
<td>8’119</td>
</tr>
<tr>
<td>Vienna</td>
<td>2016</td>
<td>7’823</td>
</tr>
<tr>
<td>Barcelona</td>
<td>2015</td>
<td>7’681</td>
</tr>
<tr>
<td>Copenhagen</td>
<td>2014</td>
<td>7’387</td>
</tr>
</tbody>
</table>

108 countries
Scientific Programme – Abstracts

Regular Abstracts Submission:
• Opened: end of October 2023
• First deadline: 15 January 2024
• Extended deadline: 22 January 2024

→ 1741 abstracts submitted for EAACI Congress 2024

Regular Abstracts Submission:
• Opened: 5 February 2024
• First deadline: 26 February 2024
• Extended deadline: 01 March 2024

→ 332 abstracts submitted for EAACI Congress 2024

2073 abstracts in total
120 Grants for JMA
EAACI Congress 2024 – EAACI Podcast

Access all platforms here:

Player FM  Spotify  iHeartRadio  Amazon Music  YouTube  Apple Podcasts
ISAF Hybrid 2023

📍 Rome, Italy
📅 5-7 October

International Severe Asthma Forum

EAACI.org
ISAF Hybrid 2023 – Registration Figures

372 Participants

294 in Rome

78 Online

6 countries

ISAF Hybrid 2023
5-7 October, Rome, Italy
PAAM Hybrid 2023 – Registration Figures

761 PARTICIPANTS

566 in Porto

194 Online

65 countries
VP Science
(1) EAACI Science Activity Report 2023-2024

- EAACI Journals (Allergy, PAI, CTA)
- EAACI Fellowship program & EAACI Ukraine Fellowship
- EAACI Sections, Interest Groups, Working Groups, JMA
- EAACI Task Forces
- EAACI Scientific Awards

- EAACI PhARF Award
- EAACI Allergopharma Award
- EAACI Science Committee (J. Sastre/ M. Worm, J. Kappen)
- EAACI Research and Outreach Committee (ROC) (I. Agache/ D. Barber)
- EAACI Methodology Committee (W. Canonica) – McMaster Training for JM/Next Generation Guidelines/Real World Data/GRADE Methodology

Advancing Research Excellence through EAACI

Journals (Allergy, PAI, CTA)

Fellowship program

Sections, Interest Groups, Working Groups, JMA

Task Forces

Scientific Awards

VP Science

Science Committee
- Sections, IG, WG
- TF

ROC
- WG
- TF

www.eaaci.org
#EAACIcongress
(2) EAACI Science Activity Report 2023-2024

• Fellowships: Research and Clinical/Ukraine (short- and long-term) 2023/2024 (13/17 FS)
  ✓ Implemented new type of fellowship for supporting Ukrainian candidates
  ✓ Implemented new type of fellowship for Clinical Long Term Fellows


• 2023: 20 Position Papers/ Task Force Reports published
  2024: 10 Position Papers/ Task Force Reports published / 11 ongoing

• 3 Journals (IF 2023 - projected):
  Allergy (15.7)
  PAI (5.0)
  CTA (4.5)
VP Education & Specialty
**Allergy School on Insect Venom Hypersensitivity and Mastocytosis**

**Bilbao, Spain, 19-21 September 2024**

**Venue:** Euskalduna Congress Center

**Main Topics:**
- Exploring the link between Hymenoptera venom allergy and mast cell diseases
- Exploring Hymenoptera venom allergy and immunotherapy
- Handling VIT adverse reactions

**Scientific Programme:**
- 17 Faculty members
- Expected 120 Participants
- Registration & Abstracts is open
- €14,600 confirmed sponsorship income as of 24.05

**Budget estimate**

<table>
<thead>
<tr>
<th>Registration Income</th>
<th>Sponsors Income</th>
<th>Costs</th>
<th>Result incl. EAACI support (€ 40k)</th>
</tr>
</thead>
<tbody>
<tr>
<td>€ 43’000</td>
<td>€ 14’600</td>
<td>€ 94’000</td>
<td>~ break-even</td>
</tr>
</tbody>
</table>

*realistic scenario: total 120 participants including faculty + € 14’600 sponsorship*
# Master Class on Planetary Health and Sustainability, Malaga, Spain
4-5 October 2024

## The Organising Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Torres</td>
<td>Chair</td>
</tr>
<tr>
<td>Karl Naudeau</td>
<td>United States, University of Malaga, 2024</td>
</tr>
<tr>
<td>Ioana Agache</td>
<td>Romania, University of Malaga, 2024</td>
</tr>
<tr>
<td>Cemal Akkis</td>
<td>Scientific Programme Committee</td>
</tr>
<tr>
<td>Marek Jutel</td>
<td>Poland, University of Malaga, 2024</td>
</tr>
<tr>
<td>Tomas Chivato</td>
<td>Spain, EAACI 2024 Education &amp; Speciality</td>
</tr>
</tbody>
</table>

## Venue
University of Malaga, Faculty of Medicine

## Main Topics
- World Vision of Climate and Sustainability
- Climate and Health Access
- Climate Change and the Biosphere

## Scientific Programme
- 24 Faculty members → International well-known Key Opinion Leaders in the field
- Expected 100 Participants
- Registration & Case submission is open
- Introduced new Interactive sessions

## Budget estimate*

<table>
<thead>
<tr>
<th></th>
<th>Income</th>
<th>Sponsors Income</th>
<th>Costs</th>
<th>Result incl. EAACI support (€ 40k)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>€ 29’000</td>
<td>€ 5’000</td>
<td>€ 72’500</td>
<td>~ break-even</td>
</tr>
</tbody>
</table>

*realistic scenario: total 75 participants including faculty + min.5k sponsorship income
Educational events overview 2025

- **Winter School**
  - Basic Immunology
  - Schladming, Austria
  - 30 January – 02 February

- **Master Class**
  - Practical aspects of biologicals and small molecules application in allergic diseases
  - Warsaw, Poland
  - Spring 2025

- **Allergy School**
  - Allergen Immunotherapy
  - Cappadocia, Turkey
  - Spring 2025

- **Allergy School**
  - Allergy and Sports: Current and Future Trends
  - TBD, Autumn 2025
  - (postponed from 2021 due to COVID-19)

- **Master Class**
  - Primary Atopic Disorder
  - Istanbul, Turkey
  - Autumn 2025

Jan | Febr | March | April | Sept | Oct
EAACI/UEMS Knowledge Exam 2024

- Application: 24 submitted, 64 is pending
- Application deadline: 03 July 2024
- Next steps: review + registration
- Exam takes place: 14 October 2024
- Digital format
- IML as question pool and quality provider
- CYIM confirmed provider

Budget estimate*

<table>
<thead>
<tr>
<th>Registration Income (incl. UEMS support)</th>
<th>Costs</th>
<th>Result incl. EAACI support (€ 30k)</th>
</tr>
</thead>
<tbody>
<tr>
<td>€ 17’000</td>
<td>€ 35’500</td>
<td>€ 10’000 (underspent budget)</td>
</tr>
</tbody>
</table>

*realistic scenario: total 100 participants
Knowledge Hub Educational Courses

Content Uploaded:

✓ T2 Diseases
  o Module 1 – Pathogenetic mechanisms, endotypes and biomarkers
  o First CME Accredited Module (2022)
  o Coordinator: Ioana Agache

✓ Drug Allergy
  o Module 1 – Diagnosis of drug allergy
  o CME Accredited Module (2024)
  o Coordinator: Asli Akkor

✓ Recurrent Angioedema – State of the Art and Future Directions
  o Coordinator: Asli Akkor

✓ Drug Hypersensitivity Module
  o Coordinator: Asli Akkor

✓ Artificial Intelligence
  o Coordinator: Mohamed Shamji

✓ Effective Transition of Adolescents and Young Adults with Allergy and Asthma
  o Coordinators: Graham Roberts and Marta Vazquez-Ortiz

Other ongoing Educational Courses:

✓ Safety JAK inhibitors module
  o Coordinator: Ioana Agache

✓ Mast Cell Diseases
  o Coordinator: Patrizia Bonadonna

Key strategic for 2024-2026

- grow the total registration numbers
- improve the admin processes for a more efficient CME application
- increase the number of CME accredited modules
<table>
<thead>
<tr>
<th>Society Name</th>
<th>Congress Dates</th>
<th>City, Country</th>
<th>Society Name</th>
<th>Congress Dates</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSACI Global Allergy Symposium</td>
<td>26 January 2024</td>
<td>ONLINE</td>
<td>European Congress of Immunology</td>
<td>01 -04 September 2024</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>AAAAI 2024</td>
<td>23-26 February 2024</td>
<td>Washington DC</td>
<td>Peruvian Immunology and Pediatric Allergy</td>
<td>18 - 20 September 2024</td>
<td>Lima, Peru</td>
</tr>
<tr>
<td>RSACI 2024</td>
<td>04 - 06 April 2024</td>
<td>Bucharest, Romania</td>
<td>World Allergy Congress WAC</td>
<td>27 - 29 September 2024</td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td>Kazakhstan Society</td>
<td>11 - 12 April 2024</td>
<td>Almaty, Kazakhstan</td>
<td>ABEFORCAL</td>
<td>04 - 05 October 2024</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>Turkish Thoracic Society</td>
<td>29 April 2024</td>
<td>Kyrenia, Republic of Northern Cyprus</td>
<td>Polish Society of Allergology</td>
<td>09 - 12 October 2024</td>
<td>Krakow, Poland</td>
</tr>
<tr>
<td>SIAIP Italy</td>
<td>02 - 04 May 2024</td>
<td>Genoa, Italy</td>
<td>Japanese Society of Allergology (USA)</td>
<td>18 - 20 October 2024</td>
<td>Kyoto, Japan</td>
</tr>
<tr>
<td>GAACI 2024</td>
<td>08 - 10 May 2024</td>
<td>Tbilisi, Georgia</td>
<td>ACAAI</td>
<td>24 -28 October 2024</td>
<td>Boston, USA</td>
</tr>
<tr>
<td>KAAACI 2024</td>
<td>10 - 11 May 2024</td>
<td>Seoul, Korea</td>
<td>Bulgarian Allergy Society</td>
<td>14 - 15 November 2024</td>
<td>Sofia, Bulgaria</td>
</tr>
<tr>
<td>Mexican College of Clinic Immunology and Allergy (CMICA)</td>
<td>5 – 8 June 2024</td>
<td>León Guanajuato, México</td>
<td>ASBAI Brazil</td>
<td>14 - 17 November 2024</td>
<td>Salvador Bahia, Brazil</td>
</tr>
<tr>
<td>FOCIS 2024</td>
<td>18 - 21 June 2024</td>
<td>San Francisco, USA</td>
<td>Turkish National Society</td>
<td>27 November - 01 December 2024</td>
<td>Antalya, Turkey</td>
</tr>
<tr>
<td>AAAeIC Congress</td>
<td>08 - 10 August 2024</td>
<td>Buenos Aires</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
EAACI General Assembly Meeting

EAACI Congress 2024
31 May - 03 June 2024
Valencia, Spain

Ludger Klimek
EAACI VP Communications
EAACI produces a broad portfolio of scientific content, position papers, guidelines etc for its members and the community. Adequate distribution of these scientific contents has always been an essential aim of our organisation. The Scientific Communications Committee combines an enthusiastic team working on the optimal communication of scientific content created within the academy via the corporate and patient websites, social media and EAACI Review.

**About the Scientific Communications Committee:**

- EAACI produces a broad portfolio of scientific content, position papers, guidelines etc for its members and the community.
- Adequate distribution of these scientific contents has always been an essential aim of our organisation.
- The Scientific Communications Committee combines an enthusiastic team working on the optimal communication of scientific content created within the academy via the corporate and patient websites, social media and EAACI Review.
Navigating the new EAACI website

As you will already have seen, the new EAACI website is finally online with clean, linear graphics in which yellow and blue colors predominate.

The new menu ribbon across the top of the screen has been simplified, leaving four main items: EAACI, Events, Professionals, and Patients. Moving the mouse cursor over one of these items allows you to view items in the submenus with a brief description of their content.

Of the four main items on the menu, the “Patients” section immediately catches the eye, since it was absent in the previous version of the website and was a separate entity. From now on it is an autonomous section of the EAACI website, and a link in the Patient section takes you straight to all the patient content available in a dedicated section of the EAACI Knowledge Hub. Also on the main menu ribbon, you can find a button for those wanting to become EAACI members, as well as the search button (the magnifying glass icon) and finally the personal account button (head and shoulders icon) which takes you to the MyEAACI Portal and the sections connected to membership (EAACI Journal, My Membership, CME Certificates).

Welcome to the EAACI Knowledge Hub

A place to learn about the most recent developments in the allergy, asthma and immunology fields, as well as exchange with experts.
Social Media posts are regularly uploaded online to promote educational modules on X platform (Twitter), Facebook and LinkedIn.
EAACI visibility engaging microblogging JM community on X/Twitter

EAACI JM @EAACI_JM · Jan 30
#EAACIW23 In Davos is over! congratulations to all junior members for their hard work, enthusiasm and excellent contribution that made this meeting a success! we hope to see you at the next Winter School, and in the other activities organised by @EAACI @EAACI_HQ

Alexandra Santos @alex_santostos
Guided tour of SIAF by @AdikisCezmi! himself! What a privilege...
#EAACIW2023

Rubén @rubén1991 · Jan 27
For the first time, and due to the 20th anniversary of the #EAACIW23 special workshop sessions are held. There, the relationship between environment and immunology is discussed in small groups of enthusiastic JM participants. @EAACI @EAACI_HQ

Matthew Burgess @budgjettheli · Jan 29
Returning to the originator of the #EAACIW23 with a comprehensive talk on the numerous effects of modern environmental factors on our epithelial barriers
EAACI Review: a new perspective for promoting all EAACI activities
EAACI Review: priorities for annual congress and focused meetings

EAACI Congress: top priority

Empowering Allergy and Immunology: Uniting for Innovation at EAACI Congress 2024

Dear EAACI Review readers

Scientific Highlights at EAACI 2024: What to look out for this year

EAACI Congress: social activities and venue

Valencia: the place to be this year for allergists and clinical immunologists

The EAACI Congress 2024 will be held in Valencia, Spain, from 30th of May to 2nd of June 2024. From the EAACI we encourage you to attend probably the biggest Congress in Allergy throughout the world. Under the banner of “Revolutionizing Allergy Care through the Power of Data Science” the EAACI wants to emphasize the significance of Allergy and Clinical Immunology through Personalized Care Data Science and the One Health approach. Valencia is a charming and vibrant city. A place of contrasts that awakens the traveler with a beautiful historic center along with modern buildings. This is a city where one can experience a blend of history and modernity, culture, and lifestyle. The city offers a wide range of attractions including art, architecture, and outdoor activities for everyone.

Join the Beat Allergy Walk & Run at EAACI Congress 2024

Dear EAACI members

EAACI Hybrid Congress 2023: an inspiring glimpse into the future of allergy and immunology

The EAACI Hybrid Congress 2023 held in Hamburg, Germany from June 20th to 22nd, was a resounding success, bringing together professionals, researchers, and students at the forefront of allergy, asthma, and clinical immunology. The dynamic program featured renowned experts, innovative research, and interactive sessions, providing participants with an opportunity to explore the latest breakthroughs, treatment options, and strategies in the field.

Regardless of their background, whether healthcare professionals, researchers, or students, attendees discovered an invaluable platform to expand their knowledge and network with peers. The event showcased cutting-edge research and practical applications in the field, offering valuable insights into the future of allergy and immunology.

Join us in Hamburg for the next iteration of this inspiring congress, where we will continue to advance our understanding and commitment to improving the lives of those affected by allergy and immunological disorders.
EAACI Review puts all eLearning resources in the spotlight

Support for dissemination of the new nomenclature of allergic diseases and hypersensitivity reactions

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs. An EAACI position paper published in Allergy

W
We are excited to share a new classification of allergic disorders focusing on disease mechanisms that promote to resolve or transmitted personalized disease management. The classification is that of a key role in understanding and managing allergic diseases, aligning with advancements in patient tailored treatments and precision medicine. EAACI, as a global allergy, science, and education leader, has spearheaded this initiative. The position paper, now available in Allergy, introduces a groundbreaking perspective on allergic disorders, emphasizing the underlying mechanisms of these diseases. The rapid development in precision medicine, such as molecular diagnostics and digital technologies, imaging, and genetic and epigenetic editing, necessitates a more nuanced approach. This shift is crucial for moving towards precision and personalized medicine in allergy treatment and management. This new classification is expected to transform how healthcare professionals approach allergic diseases. It delves into the roles of immune competent cells, tissue changes, the impact of microbial infections, and the influence of genetic and epigenetic factors. This new approach offers a more comprehensive understanding of allergic conditions, with a focus on the possible protective mechanisms in the epithelial barrier in the skin, respiratory tract, and gut. The widespread adoption of this new nomenclature is vital for developing immune-mediated disease management. It offers the way for innovative diagnostic tools, improved therapies, and enhanced disease management strategies. Future research will likely focus on novel, targeted immune-based therapies, including biologics and allergen immunotherapy, and approaches to modify the human microbiome. We believe that the true value of an idea is in its broad application. The new nomenclature for allergic diseases developed by EAACI holds great promise for healthcare professionals and patients alike, offering new pathways to manage and potentially cure allergic diseases. This article is a must-read for anyone interested in the latest developments in allergy research and treatment.

Presentation of eLearning resources and opportunities using Website links

Molecular Allergology User’s Guide in EAACI Review

Explore and Refresh your Knowledge of Molecular Allergology with MAUG 2.0!

In the past four decades, innovation in biotechnology and technology has facilitated the identification and production of well-identified, extremely pure molecules for diagnostic and therapeutic use, including allergens, for the management of allergic diseases. In addition to individual allergens, step-by-step test systems have evolved, enabling the simultaneous detection of specific allergens and a specific therapeutic tool directed towards this allergen.

To give a structured overview of the biological features of allergenic molecules and the allergen-specific diagnostic value of molecular allergens, the first edition of the EAACI Molecular Allergology User’s Guide (MAUG v1.0) was launched in 2018, and rapidly became the reference for diagnostic, research, and interventional medical and scientific communities.

Since then, researchers have discovered novel allergens, as well as allergen-specific diagnostic tools, due to the introduction of new test systems (like multiplex immunoassays). The expanding knowledge on the allergenicity of specific allergens has led to the development of new allergen-specific tests, enabling the detection of specific allergens and their association with allergic disease. The new edition of the MAUG 2.0 provides an update on the latest allergen-specific tests and the associated allergen-specific IgE levels, reflecting the latest advances in the field. Additionally, new allergen-specific tests are being developed and introduced, expanding the range of available diagnostic tools.

The MAUG 2.0 is a comprehensive resource for healthcare professionals, allergists, and researchers, providing up-to-date information on the latest developments in molecular allergology. It serves as a valuable tool for enhancing the understanding of molecular allergology and its application in clinical practice, research, and education. Under the guidance of a renowned team of experts, the MAUG 2.0 is designed to provide essential information on the latest allergen-specific tests, their diagnostic value, and their potential applications in various settings.
Advocacy activities and EAACI beyond Europe in the EAACI Review

EAACI Review distributed various advocacy events and campaigns in which EAACI was involved

EAACI Review published posts from events with the European Parliament Interest Group on Allergy & Asthma

EAACI Beyond Europe in EAACI Review

Climate Change

Increased urbanisation and vulnerability to drought, desertification, land degradation, and other climate-related risks require a more coordinated and effective strategy to address the health impacts of climate change.

Cross-disciplinary and translational insights into AllergoOncology

Building great connections with EAACI from Canada and Australia!
## MA Mass Emails

### Summary
Comparing to prior 151 days

<table>
<thead>
<tr>
<th>Campaigns sent</th>
<th>Emails sent</th>
<th>Delivery rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>172</td>
<td>4,050,219</td>
<td>99.7% + 0.2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Open rate</th>
<th>Click rate</th>
<th>Unsubscribe rate</th>
<th>Bounce rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>32.9% — 0.0%</td>
<td>3.1% + 0.1%</td>
<td>0.1% — 0.0%</td>
<td>0.3% — 0.0%</td>
</tr>
</tbody>
</table>

- 1,329,744 opened
- 126,960 clicks
- 3,330 Unsubscribed
- 15,951 bounced
El cambio climático dispara las alergias; para 2050 el 50% de la población tendrá aversión al polen

Las altas temperaturas y la contaminación han aumentado la hiperesensibilidad al polen en las últimas décadas. Tras las lluvias recientes, los médicos prevén una mayor concentración de alérgenos.

La democratización de las alergias

El cambio climático, la contaminación, la globalización y accidentes son un incremento de causas y el aumento de las alergias.

El cambio climático aumenta la gravedad, prevalencia y duración de las alergias respiratorias

El cambio climático prolonga la temporada de polinización de muchas especies.

Distintos factores relacionados con el cambio climático, como el calentamiento global y la contaminación, están representando una mayor prevalencia y duración de las alergias respiratorias. Este será uno de los puntos tratados en el próximo Congreso de la Academia Europea de Alergología e Inmunología Clínica (EAACI) con el título de "Cover the Latest Developments in Allergic and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain".

Así afecta el cambio climático a las personas alérgicas

Los alergólogos han observado un aumento de otros tipos de alergias además de las respiratorias, como las alimentarias, las alérgicas a los medicamentos y dermatitis atópica, que derivan también de factores ambientales.
ALLERGY AND AIRWAY RESEARCH CENTER
WIESBADEN-GERMANY
Thanks to all the wonderful people at EAACI !!!
Thanks to:

- Headquarters,
- all Sections, WG´s, ROC, Committee´s etc. pp
- the entire EAACI family,
- but most of all:
Thanks to:

Marketing & Communications

Yaozi Moreno
Marketing & Communications Officer

Maria Cubel
Marketing & Communications Officer

Pablo Frieyro
Marketing & Communications Officer
I will always be an EAACI-ean!
Approval of the Secretary General and Vice-Presidents’ reports
Treasurer report
Table of Content

1. Financial Report as of December 31st 2023
2. Vote for Treasurer report
3. Re-appointment of the Auditor
4. Budget 2024
Audited financial report as of 31st December 2023

<table>
<thead>
<tr>
<th>EAACI - Profit &amp; Loss Statement</th>
<th>01.01. - 31.12.2023</th>
<th>Budget approved by GA 11.6.2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Income</td>
<td>7'445'754</td>
<td>5'220'000</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>5'120'140</td>
<td>6'128'250</td>
</tr>
<tr>
<td>Result</td>
<td>2'325'614</td>
<td>-1'157'250</td>
</tr>
<tr>
<td>Adjustment Investment to market value</td>
<td>17'258</td>
<td>0</td>
</tr>
<tr>
<td>Result 2023</td>
<td>2'342'872</td>
<td>-1'157'250</td>
</tr>
</tbody>
</table>
## Audited financial report as of 31st December 2023

<table>
<thead>
<tr>
<th>EAACI - Profit &amp; Loss Statement</th>
<th>01.01. - 31.12.2023</th>
<th>Budget approved by GA 11.6.2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>7'445'754</td>
<td>5'220'000</td>
</tr>
<tr>
<td>Founder Sponsors</td>
<td>2'425'475</td>
<td>2'040'000</td>
</tr>
<tr>
<td>Congress &amp; Events</td>
<td>3'391'292</td>
<td>1'825'000</td>
</tr>
<tr>
<td>Education</td>
<td>77'818</td>
<td>225'000</td>
</tr>
<tr>
<td>Communication &amp; Membership</td>
<td>285'342</td>
<td>300'000</td>
</tr>
<tr>
<td>Scientific Activities (Journals)</td>
<td>575'260</td>
<td>450'000</td>
</tr>
<tr>
<td>External Strategic Activities</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Internal Activities</td>
<td>143'589</td>
<td>48'500</td>
</tr>
<tr>
<td>Financial Income</td>
<td>246'978</td>
<td>31'500</td>
</tr>
<tr>
<td>Extraordinary (rollover)</td>
<td>300'000</td>
<td>300'000</td>
</tr>
</tbody>
</table>
Audited financial report as of 31st December 2023

<table>
<thead>
<tr>
<th>EAACI - Profit &amp; Loss Statement</th>
<th>01.01. - 31.12.2023</th>
<th>Budget approved by GA 11.6.2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Expenditures</strong></td>
<td>5'120'140</td>
<td>6'128'250</td>
</tr>
<tr>
<td>Congress and Events</td>
<td>74'797</td>
<td>0</td>
</tr>
<tr>
<td>Education</td>
<td>459'225</td>
<td>454'500</td>
</tr>
<tr>
<td>Communications and Membership</td>
<td>165'760</td>
<td>166'200</td>
</tr>
<tr>
<td>Scientific Activities</td>
<td>1'214'384</td>
<td>2'367'300</td>
</tr>
<tr>
<td>Internal Activities</td>
<td>2'875'712</td>
<td>3'060'250</td>
</tr>
<tr>
<td>Financial Expenses</td>
<td>14'934</td>
<td>50'000</td>
</tr>
<tr>
<td>Extraordinary / Contingency</td>
<td>315'328</td>
<td>30'000</td>
</tr>
</tbody>
</table>
Audit Report 2023

To the General Meeting

European Academy of Allergy and Clinical Immunology

Zürich

Report of the mandatory auditors to the management

(period 01.01.2023 to 31.12.2023)

St. Gallen, 13 May 2024

fol / 3

Audit Suisse AG
Vadimistrasse 59, CH-9000 St. Gallen
info@auditsuisse.ch, www.auditsuisse.ch, +41 71 236 87 00
EXPERTsuisse zertifiziertes Unternehmen, Mitglied TREUHAND SUISSE
Mandatory Auditor’s Report to the management of
European Academy of Allergy and Clinical Immunology, Zürich

As mandatory auditors, we have audited the financial statements (balance sheet, income statement and notes) of European Academy of Allergy and Clinical Immunology, Zürich for the year ended 31.12.2023.

These financial statements (balance sheet and income statement) are the responsibility of the board of directors.

Our responsibility is to express an opinion on these financial statements based on our audit. Our audit was conducted in accordance with auditing standards promulgated by the Swiss profession, which require that an audit be planned and performed to obtain reasonable assurance about whether the financial statements are free from material misstatement. We have examined on a test basis evidence supporting the amounts and disclosures in the financial statements. We have also assessed the accounting principles used, significant estimates made and the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the accounting records and financial statements (balance sheet and income statement) comply with Swiss law.

St. Gallen, 13 May 2024

Audit Suisse AG

Christian Feller
Licensed Audit Expert

Appendix:
- Financial Statements
Approval of the Treasurer report
Budget 2024 to approve by General Assembly

<table>
<thead>
<tr>
<th>EAACI profit &amp; loss statement</th>
<th>Budget 2024 ExCom approval 18.11.2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>6'463'500</td>
</tr>
<tr>
<td><strong>Total Expenditures</strong></td>
<td>7'133'950</td>
</tr>
</tbody>
</table>
| **Deficit without projects on hold** | -670'450 |}
| **Project on hold**           | -271'600                            |
| **Deficit**                   | -942'050                            |
Approval of the Budget 2024
Re-appointment of Auditor for 2024

Audit Suisse AG
Vadianstrasse 59, CH-9000 St. Gallen
EXPERTsuisse zertifiziertes Unternehmen
Mitglied TREUHAND SUISSE
Approval of Re-appointment of Auditor
Presentation of the 2024-2026 elections for the members of the Executive Committee
## 2024 – 2026 EAACI Board of Officers

<table>
<thead>
<tr>
<th>EAACI Role</th>
<th>Family Name</th>
<th>First Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Torres</td>
<td>Maria J.</td>
<td>Spain</td>
</tr>
<tr>
<td>Secretary General</td>
<td>Shamij</td>
<td>Mohamed</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Bonadonna</td>
<td>Patrizia</td>
<td>Italy</td>
</tr>
<tr>
<td>VP Congresses</td>
<td>Moreira</td>
<td>André</td>
<td>Portugal</td>
</tr>
<tr>
<td>VP Education &amp; Specialty</td>
<td>Walusiak-Skorupa</td>
<td>Jolanta</td>
<td>Poland</td>
</tr>
<tr>
<td>VP Communications</td>
<td>Pfaar</td>
<td>Oliver</td>
<td>Germany</td>
</tr>
<tr>
<td>VP Science</td>
<td>Palomares</td>
<td>Oscar</td>
<td>Spain</td>
</tr>
<tr>
<td>Past President</td>
<td>Del Giacco</td>
<td>Stefano</td>
<td>Italy</td>
</tr>
</tbody>
</table>
# 2024 – 2026 EAACI Executive Committee

<table>
<thead>
<tr>
<th>EAACI Role</th>
<th>Family Name</th>
<th>First Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair, Asthma Section</td>
<td>Adcock</td>
<td>Ian</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair, Dermatology Section</td>
<td>Barbaud</td>
<td>Annick</td>
<td>France</td>
</tr>
<tr>
<td>Chair, ENT Section</td>
<td>Chaker</td>
<td>Adam</td>
<td>Germany</td>
</tr>
<tr>
<td>Chair, Basic &amp; Clinical Immunology Section</td>
<td>Santos</td>
<td>Alexandra</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chair, Pediatrics Section</td>
<td>Tsabouri</td>
<td>Sophia</td>
<td>Greece</td>
</tr>
<tr>
<td>Chair, Allied Health &amp; Primary Care Section</td>
<td>Ozdemir</td>
<td>Cevdet</td>
<td>Turkey</td>
</tr>
<tr>
<td>Chair, JM Assembly</td>
<td>Karavelia</td>
<td>Aspasia</td>
<td>Greece</td>
</tr>
<tr>
<td>IG-WG Representative</td>
<td>Pitsios</td>
<td>Constantinos</td>
<td>Cyprus</td>
</tr>
<tr>
<td>IG-WG Representative</td>
<td>Vega Castro</td>
<td>Arantza</td>
<td>Spain</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Sokolowska</td>
<td>Milena</td>
<td>Poland</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Panaitescu</td>
<td>Carmen</td>
<td>Romania</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Terreehorst</td>
<td>Ingrid</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Annesi-Maesano</td>
<td>Isabella</td>
<td>France</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Celik</td>
<td>Gülfem</td>
<td>Turkey</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td>Escribese</td>
<td>Maria</td>
<td>Spain</td>
</tr>
</tbody>
</table>
Approval of the 2024-2026 elections for the members of the Executive Committee
Proposal for Constitution changes
Article 3 – EAACI Activities

EAACI may pursue all activities that directly or indirectly promote the purpose of the Academy. Moreover, To promote the purpose of the Academy, it may, among other things, manage real estate, use and sell services, licenses, patents and other intellectual property.

In addition, EAACI may also establish legal entities, branches and representative offices in and outside Switzerland to promote its purpose.

All EAACI activities adhere to the general principles of transparency and fairness.

Article 8A - Competencies

[...]

The Executive Committee determines and grants the signatory powers for EAACI which in general shall be collective signing powers by three, with one being the President. Exception to this may arise due to legal requirements.

[...]
Approval of Constitution changes
EAACI President 2024-2026 address
My mission as EAACI president

Reinforce EAACI as the most successful Allergy and Clinical Immunology Society in the field

1. Boost the achievements of previous presidents
2. Maintain EAACI commitment to its core values
3. Support the Allergy discipline
4. Ensure financial safety
5. Promote teamwork, efficiency and quality
My vision of EAACI

EAACI is the primary reference about Allergy, Asthma and Clinical Immunology.

EAACI should be a society closely connected to its members.

EAACI is obliged to mentor and enroll the future leaders of the Allergy discipline.

EAACI should be the primary professional platform for all stakeholders.
My key pillars

- High quality science supporting prevention and cure of allergic diseases and asthma
- Tailored educational programmes complementing EAACI science and research strategy
- Renew the EAACI brand
- Build on the strength of EAACI membership
- Maintain solid finances, organizational effectiveness and quality management
Specific actions to support high quality science

- Involve sections, IGs and WGs, and patients in EAACI's science strategy
- Include JM in all decision processes of EAACI's science strategy
- Support front-science published in EAACI journals: Allergy, PAI, CTA
- Communicate science in an efficient manner to the rest of the world
- Lobby at the EU level to include allergy as a funding research priority
- Include mobile health, omics, RWE and AI and assessment of QoL in our scientific activity
Specific actions to boost the value of EAACI events

- Increase the **number of participants** and sponsors and provide them with **entire satisfaction**
- Increase **travel grants** for JMs and generate a **specific track** for them
- Improve the **scientific programme** by involving individual members, sections, IGs, and local flavor
- Reinforce the role of the **Scientific Committee** for the identification of the best presenters and the most novel and relevant scientific findings
- Measure **satisfaction** of members, delegates and sponsors with the events on a regular basis
- Implement a **healthy economy** and budget
- Promote **social interaction** transforming ‘entertainment’ into ‘networking’
Specific actions for tailored educational programmes

- Adapt and make accessible the content of EAACI events to patients and society
- Foster EAACI educational projects, and expand the digital offer
- Embrace and educate general practitioners interested in asthma and allergic diseases
- Create the Tailored Education Committee, liaising with all relevant stakeholders
- Update the European training curricula in Allergy and Clinical Immunology (EAACI Specialty/CME Committee and NAS)
- Develop an effective marketing plan that supports the need of Allergy specialists in public health systems
Specific actions to renew the EAACI brand

**Long-term strategy**
- Develop a 4-year **communication plan** with the VP Communication
- Develop EAACI **public campaigns**, launched every year to support major areas of allergy
- Develop monthly **press releases** to inform about science, education and events
- Develop an “**EAACI brand**” for communication with members and patients

**To optimise Outreach**
- Maintain **bilateral agreements** with external organisations in order to undertake coordinated lobbying at the EU level
- Create a **Health Information Technology Committee** responsible for an innovative information infrastructure
- Establish **effective communication** with all relevant stakeholders
Specific actions to strengthen the value of EAACI membership

- **Monitor** regularly the needs of members to help create tailored communication pathways
- **Give visibility to the support** that the members can get from EAACI
- **Continue honoring our members** as EAACI Fellows, EAACI Awards and EAACI loyalty programmes
- **Foster the relationship with NAS** through the NAS Committee and dual membership
- **Activate the International Society Council** with contact points in the ExCom
- **Facilitate that Patients, Allied Health and Primary Care groups contribute to our strategic thinking**
- **Promote that JMs lead** specific educational and communication initiatives, including a SoMe Network
Specific actions to strengthen finances, organization and management

Implement a **HQ development plan** with newly defined roles and responsibilities ensuring optimal organisational efficiency

Increase **internal communication** and involve ExCom members in the everyday running of EAACI

Create a **Quality Committee** to work together with the SG, Treasurer, and HQ Manager to organise the processes

Develop a **mid- and long-term fundraising strategy** allowing EAACI to keep its financial strength, responsibility, transparency, and independence

Develop **respectful collaboration with “Founder Sponsors”**, supporting scientific communication by developing strategic partnerships
KEY DELIVERABLES
OF MY PRESIDENTIAL PLAN

Health Information Technology Committee

Recruit JM for leading positions in EAACI’s educational and communication projects

Tailored Education Committee

Mid/long-term fundraising and investment strategy

HQ development plan

Quality Committee
## Research and Outreach as Priority

<table>
<thead>
<tr>
<th>EAACI Networks of Excellence in Allergy, Asthma and Clinical Immunology Research, Education and Care</th>
<th>EAACI partnership in international research consortia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EIRC</td>
</tr>
<tr>
<td>EAACI Network for Clinical Trials – ENCT</td>
<td>EAACI Data collection about allergic diseases and asthma and their impact on individuals, society and health economy</td>
</tr>
<tr>
<td></td>
<td>Head-Registry Patients Impact</td>
</tr>
</tbody>
</table>

EAACI Journals
I am committed to

- Achieve measurable results

- Elaborate a strategic programme for different areas in collaboration with the BoO, the ExCom and rest of EAACI family

- Build a team based on mutual respect, transparency, empathy, and with an open-minded spirit

- Ensure that everyone feels included and motivated for the well-being of the Academy and the Allergy discipline

The goal is to maintain global leadership
"EAACI - dedicated to allergy science, committed to your health"
Q&A Session